Bjornsti M[au] - Search Results

Year	Number of Results
1981	1
1982	1
1983	1
1984	1
1985	1
1987	2
1988	1
1989	2
1993	3
1994	1
1995	4
1996	1
1997	2
1998	5
1999	7
2000	2
2001	3
2002	3
2003	3
2004	7
2005	2
2006	2
2007	7
2008	2
2010	1
2013	3
2015	4
2016	2
2017	1
2019	2
2020	1
2022	0

1

DNA topoisomerase-targeting chemotherapeutics: what's new?

Cuya SM, Bjornsti MA, van Waardenburg RCAM. Cuya SM, et al. Among authors: bjornsti ma. Cancer Chemother Pharmacol. 2017 Jul;80(1):1-14. doi: 10.1007/s00280-017-3334-5. Epub 2017 May 20. Cancer Chemother Pharmacol. 2017. PMID: 28528358 Review.

2

Topoisomerases and cancer chemotherapy: recent advances and unanswered questions.

Bjornsti MA, Kaufmann SH. Bjornsti MA, et al. F1000Res. 2019 Sep 30;8:F1000 Faculty Rev-1704. doi: 10.12688/f1000research.20201.1. eCollection 2019. F1000Res. 2019. PMID: 31602296 Free PMC article. Review.

3

Cancer therapeutics in yeast.

Bjornsti MA. Bjornsti MA. Cancer Cell. 2002 Oct;2(4):267-73. doi: 10.1016/s1535-6108(02)00160-5. Cancer Cell. 2002. PMID: 12398890 Free article. Review.

4

Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.

van Waardenburg RC, de Jong LA, van Eijndhoven MA, Verseyden C, Pluim D, Jansen LE, Bjornsti MA, Schellens JH. van Waardenburg RC, et al. Among authors: bjornsti ma. J Biol Chem. 2004 Dec 24;279(52):54502-9. doi: 10.1074/jbc.M410103200. Epub 2004 Oct 6. J Biol Chem. 2004. PMID: 15471886 Free article.

5

Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage.

Jacquiau HR, van Waardenburg RC, Reid RJ, Woo MH, Guo H, Johnson ES, Bjornsti MA. Jacquiau HR, et al. Among authors: bjornsti ma. J Biol Chem. 2005 Jun 24;280(25):23566-75. doi: 10.1074/jbc.M500947200. Epub 2005 Apr 6. J Biol Chem. 2005. PMID: 15817450 Free article.

6

Cellular strategies for regulating DNA supercoiling: a single-molecule perspective.

Koster DA, Crut A, Shuman S, Bjornsti MA, Dekker NH. Koster DA, et al. Among authors: bjornsti ma. Cell. 2010 Aug 20;142(4):519-30. doi: 10.1016/j.cell.2010.08.001. Cell. 2010. PMID: 20723754 Free PMC article. Review.

7

The TOR pathway: a target for cancer therapy.

Bjornsti MA, Houghton PJ. Bjornsti MA, et al. Nat Rev Cancer. 2004 May;4(5):335-48. doi: 10.1038/nrc1362. Nat Rev Cancer. 2004. PMID: 15122205 Review. No abstract available.

8

Rapamycins: mechanism of action and cellular resistance.

Huang S, Bjornsti MA, Houghton PJ. Huang S, et al. Among authors: bjornsti ma. Cancer Biol Ther. 2003 May-Jun;2(3):222-32. doi: 10.4161/cbt.2.3.360. Cancer Biol Ther. 2003. PMID: 12878853 Review.

9

Disulfide cross-links reveal conserved features of DNA topoisomerase I architecture and a role for the N terminus in clamp closure.

Palle K, Pattarello L, van der Merwe M, Losasso C, Benedetti P, Bjornsti MA. Palle K, et al. Among authors: bjornsti ma. J Biol Chem. 2008 Oct 10;283(41):27767-27775. doi: 10.1074/jbc.M804826200. Epub 2008 Aug 8. J Biol Chem. 2008. PMID: 18693244 Free PMC article.

10

Lost in translation: dysregulation of cap-dependent translation and cancer.

Bjornsti MA, Houghton PJ. Bjornsti MA, et al. Cancer Cell. 2004 Jun;5(6):519-23. doi: 10.1016/j.ccr.2004.05.027. Cancer Cell. 2004. PMID: 15193254 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results